This report was first published by Endpoints News. To see the original version, click here
Merck’s partner on an experimental antibody-drug conjugate has reported a Phase 3 win in first-line lung cancer, and will take the data to Chinese regulatory authorities.
Chengdu-based Kelun-Biotech said that a combination of its ADC sacituzumab tirumotecan, also known as sac-TMT, and Merck’s Keytruda beat Keytruda alone in patients with first-line, PD-L1-positive non-small cell lung cancer. While Kelun didn’t divulge detailed data, the combination hit the study’s primary endpoint of progression-free survival at an interim analysis.
您已閱讀22%（627字），剩余78%（2232字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。